Share on StockTwits

InterMune (NASDAQ:ITMN) CFO John Hodgman sold 1,201 shares of the stock on the open market in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $38.78, for a total value of $46,574.78. Following the transaction, the chief financial officer now directly owns 24,488 shares in the company, valued at approximately $949,645. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $39.08.

Shares of InterMune (NASDAQ:ITMN) traded up 2.28% on Thursday, hitting $40.87. The stock had a trading volume of 1,774,305 shares. InterMune has a 1-year low of $9.32 and a 1-year high of $41.24. The stock has a 50-day moving average of $35.49 and a 200-day moving average of $24.37. The company’s market cap is $4.041 billion.

InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was up 188.6% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.34 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.